STRAC ID Leads Outpatient Strategies for COVID-19 Infection
Updated: January 4, 2023

• This is a summary of recommendations from STRAC ID Leads for outpatient management of COVID-19. It reflects consensus opinion from a group of ID specialists in San Antonio. Decisions about individual patient care should be managed by patients’ physicians or providers according to individual medical needs. This document is not a substitute for advice from a personal health care provider.
• NIH and Infectious Diseases Society of America (IDSA) guidelines do not recommend non-FDA authorized/approved therapies for COVID-19 outside of a clinical trial.

Recommended by ID Leads

• Isolation – Persons diagnosed with COVID-19 should isolate at home
  • CDC updated isolation and quarantine guidelines on December 27, 2021
  • [https://www.cdc.gov/media/releases/2021/s1227-isolation-quarantine-guidance.html](https://www.cdc.gov/media/releases/2021/s1227-isolation-quarantine-guidance.html)
  • If you test positive for COVID-19 – Isolate
    ▪ Stay home for 5 days
    ▪ If you have no symptoms or your symptoms are resolving after 5 days, you can leave your house
    ▪ Continue to wear a mask around others for an additional 5 days
  • For those with severe disease (requiring hospitalization), 20 days of isolation should be considered and for those who are immunosuppressed, longer isolation times may be warranted.

• General Recommendations
  • Nutrition/hydration
  • Adequate sleep
  • Stop/limit smoking and vaping
  • Limit alcohol use
  • Acetaminophen or ibuprofen for fever

• Equipment
  • Thermometer
  • Pulse oximeter
  • Home blood pressure cuff

• Warning Signals Warranting Presentation to Health Care Setting for Evaluation
  • Oxygen saturation <94% at rest
  • Significant desaturation into 85% range upon walking
  • Persistent shortness of breath
• Persistent fever
• Decrease in mental status (e.g., confusion, lethargy)
• Significant decrease in blood pressure

Recommended in certain conditions

• Nirmatrelvir/ritonavir (Paxlovid) – FDA-authorized (EUA) oral antiviral for treatment of COVID-19 [https://www.fda.gov/media/155050/download]
  o For the treatment of mild-to-moderate coronavirus disease (COVID-19)
  o in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds)
    ▪ with positive results of direct SARS-CoV-2 testing,
    ▪ AND who are at high risk for progression to severe COVID-19, including hospitalization or death.
  o Paxlovid is available by prescription only
  o and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.
  o Not recommended in pts with severe kidney or liver impairment.
  o Limitations of authorized use
    ▪ Paxlovid is not authorized for
      • initiation of treatment in patients requiring hospitalization due to severe or critical COVID-19
      • use as pre-exposure or post-exposure prophylaxis for prevention of COVID-19.
      • use for longer than 5 consecutive days.
  o Dosage and Administration
    ▪ Paxlovid is nirmatrelvir tablets co-packaged with ritonavir tablets. Nirmatrelvir must be co-administered with ritonavir.
    ▪ Initiate Paxlovid treatment as soon as possible after diagnosis of COVID-19 and within 5 days of symptom onset.
    ▪ Dosage eGFR 60 ml/min or greater: 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet), with all three tablets taken together twice daily for 5 days.
    ▪ Dosage eGFR 30-60 ml/min: nirmatrelvir 150 mg oral with ritonavir 100 twice daily for 5 days.
  o Contraindications
    ▪ history of clinically significant hypersensitivity reactions [e.g., toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome] to its active ingredients (nirmatrelvir or ritonavir) or any other components of the product.
    ▪ with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions
      ▪ Alpha1-adrenoreceptor antagonist: alfuzosin
• Analgesics: pethidine, piroxicam, propoxyphene
• Antianginal: ranolazine
• Antiarrhythmic: amiodarone, dronedarone, flecainide, propafenone, quinidine
• Anti-gout: colchicine
• Antipsychotics: lurasidone, pimozide, clozapine
• Ergot derivatives: dihydroergotamine, ergotamine, methylergonovine
• HMG-CoA reductase inhibitors: lovastatin, simvastatin
• PDE5 inhibitor: sildenafil (Revatio®) when used for pulmonary arterial hypertension (PAH)
• Sedative/hypnotics: triazolam, oral midazolam

• Paxlovid is contraindicated with drugs that are potent CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance. Paxlovid cannot be started immediately after discontinuation of any of the following medications due to the delayed offset of the recently discontinued CYP3A inducer
  • Anticancer drugs: apalutamide
  • Anticonvulsant: carbamazepine, phenobarbital, phenytoin
  • Antimycobacterials: rifampin
  • Herbal products: St. John’s Wort (hypericum perforatum)

  o Warnings and Precautions
    o The concomitant use of Paxlovid and certain other drugs may result in potentially significant drug interactions. Consult the full prescribing information prior to and during treatment for potential drug interactions.
    o Hepatotoxicity: Hepatic transaminase elevations, clinical hepatitis, and jaundice have occurred in patients receiving ritonavir.
    o HIV-1 Drug Resistance: Paxlovid use may lead to a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection.
    o Caution with use in pregnancy due to limited data

  o Link for available COVID therapy products:
    o https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/
    o This link can be helpful for evaluating drug interactions
    o https://www.covid19-druginteractions.org/checker

  o Consider especially in immunocompromised patients
  o https://www.natap.org/2021/HIV/120321_01.htm (RCT PINETREE Study)
- Regimen: 200 mg day 1, 100 mg days 2 and 3 in first 7 days of illness
- Treatment resulted in
  - 87% reduction in hospitalization or death
  - 81% reduction in COVID-19 medically attended visits
- Consider in setting of limited mAb or oral antiviral supply

- Monoclonal Antibodies (mAbs)
  - The previously used mAbs do not have substantial activity against the omicron variant and are not currently recommended. These are:
    - Casirivimab and imdevimab (REGEN-COV, Regeneron) and
    - Bamlanivimab and estevimab (Lilly)
    - Sotrovimab
    - Bebtelovimab
  - At this time, there are no mAb choices effective for current variants

- Molnupiravir (Lagevrio) – FDA-authorized (EUA) oral antiviral for COVID-19 [https://www.fda.gov/media/155054/download](https://www.fda.gov/media/155054/download)
  - For the treatment of mild-to-moderate disease in adults
    - With positive results of direct SARS-CoV-2 viral testing, and
    - Who are at high-risk for progression to severe COVID, including hospitalization or death, and
    - For whom alternative COVID-19 treatment options authorized by FDA are not accessible or clinically appropriate.
  - Limitations on Authorized Use
    - Molnupiravir is not authorized for use in patients who are less than 18 years of age.
    - Molnupiravir is not authorized for initiation of treatment in patients requiring hospitalization due to COVID-19.
    - Benefit of treatment with molnupiravir has not been observed in subjects when treatment was initiated after hospitalization due to COVID-19.
    - Molnupiravir is not authorized for use for longer than 5 consecutive days.
    - Molnupiravir is not authorized for use as pre-exposure or as post-exposure prophylaxis for prevention of COVID-19.
  - Dosage and Administration – Available by prescription only
    - 800 mg (four 200 mg capsules) po every 12 hours
    - Take monulpiravir asap after diagnosis of COVID-19, and within 5 days of onset.
  - Warnings/Precautions
    - Embryo-Fetal Toxicity: Molnupiravir is not recommended for use during pregnancy.
Bone and Cartilage Toxicity: Molnupiravir is not authorized for use in patients less than 18 years of age because it may affect bone and cartilage growth.

- FDA-authorized (EUA) for pre-exposure prophylaxis: tixagevimab/cilgavimab (Evusheld) https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/6d1d5fea-2532-46e9-a1d4-1504f6dd41b2/6d1d5fea-2532-46e9-a1d4-1504f6dd41b2_viewable_rendition_v.pdf
  - in adults and pediatric individuals (12 years of age and older weighing at least 40 kg)
  - **Pre-exposure prophylaxis** for those:
    - Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination or
    - For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID19 vaccine component(s).

- Dosage and Administration
  - Injection: • tixagevimab 150 mg/1.5 mL (100 mg/mL) in a single-dose vial.
    (3) • cilgavimab 150 mg/1.5 mL (100 mg/mL) in a single-dose vial.

- Limitations of Authorized Use
  - Evusheld is not authorized for use in individuals:
    - For treatment of COVID-19, or
    - For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2.
  - Pre-exposure prophylaxis with Evusheld is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate to severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID-19 vaccination.
  - In individuals who have received a COVID-19 vaccine, EVUSHELD should be administered at least two weeks after vaccination.
  - Many Omicron subvariants, including the dominant strain in the U.S., are expected to be less susceptible to this agent at this time.

**Often Recommended by ID Leads**
- **Zinc lozenges**
  - Antiviral activity
  - Can decrease duration/severity of common cold
  - Well-tolerated
  - High doses over long term – GI side effects, copper deficiency

- **Vitamin D**
  - Important for immune function and an immune modulator
  - Vitamin D deficiency associated with worse outcomes
  - Vitamin D supplementation can protect against acute (non-COVID) respiratory infection
  - Supplementation in hospitalized COVID-19 pts – no difference in LOS, intubation, death
  - Consider especially for those at risk for deficiency
    - Elderly
    - Persons with melanin-rich skin
    - Persons with no or limited sun exposure
  - Dose of 2000 IU daily

  https://www.thelancet.com/journals/landia/article/PIIS2213-8587%2820%2930183-2/fulltext

  https://www.covid19treatmentguidelines.nih.gov/therapies/supplements/vitamin-d/

- **Melatonin**
  - Antioxidant and anti-inflammatory
  - Production decreased in older adults
  - Good safety profile
  - Reasonable dose is 3 mg nightly which is easily found in tablet form
  - If a smaller dose is needed due to morning grogginess, use the liquid form at 0.3 mg nightly

  https://doi.org/10.1016/j.eprac.2021.06.001

**Sometimes Recommended by ID Leads**

- **Fluvoxamine** – not authorized by FDA
Support includes - Two positive RCTs and a positive observational study
- SSRI that is an immunomodulator
- Potential mechanisms
  - Sigma-1 activation – reduces cytokine production
  - Inhibits sphingomyelinase, relevant for viral entry
  - Inhibits hyperactivation of platelets and mast cells
  - Inhibits metabolism of melatonin
  - Good safety profile
  - Side effects include nausea, which can be mitigated by taking with food
  - Inexpensive and widely available

- Positive Phase 2 study in outpatients; Dose 100 mg TID
- Primary endpoint – clinical deterioration, N=152 outpatients
- 0% (0/80) in fluvoxamine group vs 8.3% (6/72) in the placebo group. 5/6 to hospital; 4 hospitalized; P=0.009
- SAEs – 1 in fluvoxamine group (hospitalization for dehydration) vs. 6 in placebo group

Seftel D, Boulware D. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum ID 2021;8(2) ofab050
https://doi.org/10.1093/ofid/ofab050 1 Feb 2021
- Dose 50 mg twice daily
- 0/65 pts on fluvoxamine hospitalized; 0/65 residual sx
- 6/48 (12/5%) on observation hospitalized; 29/48 (60%) residual sx

NIH multicenter outpatient study underway – Results pending
- One option is fluvoxamine dosed 50 mg twice daily x 10 days
- https://activ6study.org

**Famotidine**
- Histamine-2 receptor antagonist may modulate cytokine storm
- Positive preliminary studies warrant further investigation
- Good safety profile
- Would not exceed approved dose of 40 mg daily


**Self-proning**
- May be used in cooperative patients who have mild desaturation and are comfortable in prone position
- Benefit usually noticed within 5-10 minutes
- Usual interval 30-120 minutes
- Sequence: prone, left lateral decubitus, right lateral decubitus, upright sitting
Only maintain if comfortable for patient
Avoid with pregnancy, spinal instability, face or neck trauma, hemoptysis


No Recommendation

- **Aspirin (ASA)**
  - Preliminary observational study showed less complications in hospitalized patients who had received ASA within 24 hours of admission or 7 days prior to admission
  - Risk of bleeding
  - Avoid in children due to Reye’s Syndrome


- **Nasal irrigation with 1% povidone-iodine by volume (0.1% solution by mass)**
  - Iodine should not be used in thyroid conditions or pregnancy
  - For 8 oz, no more than ½ teaspoon (2.5 ml of 10% povidone-iodine solution) in the 8 oz
  - User must be competent in using irrigation device, including proper cleaning
  - Bottled or purified water should be used


- **Probiotic *Lactobacillus rhamnosus***
  - Some evidence to suggest immunomodulatory effect in sepsis
  - Clinical trial ongoing in COVID-19

  [https://sites.duke.edu/protectehc/about-our-study/](https://sites.duke.edu/protectehc/about-our-study/)

Not Recommended Until More Information is Available

- **Colchicine**
  - Preliminary positive study in hospitalized patients
  - Side effects: GI (diarrhea, nausea/vomiting, abdominal pain), muscle weakness, numbness/tingling, allergic reaction

  - Additional Information:
    - COLCORONA Study
    - [https://www.medrxiv.org/content/10.1101/2021.01.26.21250494v1.full.pdf](https://www.medrxiv.org/content/10.1101/2021.01.26.21250494v1.full.pdf)
Dose 0.5 mg BID x 3 days and once daily thereafter for total of 30 days
Study in non-hospitalized pts. Primary endpoint death or hospitalization
COVID dx by PCR or clinical criteria, N=4488
Death or hospitalization decreased 1% (4.7% vs 5.8%; OR 0.79, p 0.08)
PCR confirmed Covid, N=4159
Death or hospitalization decreased 1.4% (4.6% vs 6.0%, p 0.04)
Diarrhea more common in the colchicine group (13.7% vs 7.3%, p 0.0001)
Pulmonary embolism more common in the colchicine group 0.5% vs. 0.1%, 11 vs 2 pts, p 0.01
Generic colchicine no longer available; based on our sources 30 days of colchicine costs ~$250

Not Recommended
- Oral corticosteroids – not recommended in outpatients not on oxygen for COVID-19
  - RECOVERY trial showed benefit for hospitalized pts requiring supplemental oxygen.
  - Hospitalized pts who did not require oxygen had worse clinical outcomes on steroids
- Ivermectin – multiple well-done, randomized clinical trials have not shown benefit.
  https://www.nejm.org/doi/full/10.1056/NEJMoa2115869#:~:text=A%20large%20collaboration%20of%20clinical,or%20better%20quality%20were%20examined.
- Hydroxychloroquine
  - Multiple well-conducted studies show negative results
  - Side effects – GI and prolonged QT interval
    Saag MS. Misguided use of hydroxychloroquine for COVID-19. Jour Amer Med Assoc Published online November 9, 2020
- Azithromycin and Doxycycline
  - Studies largely done with hydroxychloroquine
  - Well-conducted trials have been negative
  - Unnecessary use contributes to antimicrobial resistance
  - Side effects – prolonged QT interval, GI, C. difficile colitis
- Vitamin C
  - Antioxidant and anti-inflammatory
  - Studied in sepsis with variable outcomes
  - Few safety concerns
  - COVID-19 studies have been IV doses in hospitalized patients
  - Clinical trials ongoing
- Metformin
  - Two randomized trials have not shown benefit
Those receiving metformin for underlying condition should continue this therapy as directed by their health care provider.

NIH Guidelines https://www.covid19treatmentguidelines.nih.gov/


Updated: January 4, 2023